Vancomycin for treatment of invasive, multi-drug resistant Staphylococcus aureus infections

Bibliography

• CHANG FY, PEACOCK JE, Jr, MUSHER DM et al.: Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (2003) 82(5):333-339.
   PubMed Web of Science ®Google Scholar
• CHANG WN, LU CH, WU JJ et al.: Staphylococcus aureus meningitis in adults: a clinical comparison of infections caused by methicillin-resistant and methicillin-sensitive strains. Infection (2001) 29(5):245-250.
   PubMed Web of Science ®Google Scholar
• FAGON JY, MAILLET JM, NOVARA A: Hospital-acquired pneumonia: methicillin resistance and intensive care unit admission. Am. J. Med. (1998) 104(5A):17S-23S.
   PubMed Web of Science ®Google Scholar
• HAU T: Efficacy and safety of linezolid in the treatment of skin and soft tissue infections. Eur. J. Clin. Micobiol. Infect. Dis. (2002) 21(7):491-498.
   PubMed Web of Science ®Google Scholar
• LOWY FD: Staphylococcus aureus infections. New Engl. J. Med. (1998) 339(8):520-532.
   PubMed Web of Science ®Google Scholar
• MANDAL S, BERENDT AR, PEACOCK SJ: Staphylococcus aureus bone and joint infection. J. Infect. (2002) 44(3):143-151.
   PubMed Web of Science ®Google Scholar
• MARKS MI: Clinical significance of Staphylococcus aureus in cystic fibrosis. Infection (1990) 18(1):53-56.
   PubMed Web of Science ®Google Scholar
• MEKONTSO-DESSAP A, KIRSCH M, BRUN-BUISSON C, LOISANCE D: Poststernotomy mediastinitis due to Staphylococcus aureus: comparison of methicillin-resistant and methicillin-susceptible cases. Clin. Infect. Dis. (2001) 32(6):877-883.
   PubMed Web of Science ®Google Scholar
• PETTI CA, FOWLER VG, Jr: Staphylococcus aureus bacteremia and endocarditis. Infect. Dis. Clin. North Am. (2002) 16(2):413-435.
   PubMed Web of Science ®Google Scholar
• SADER HS, JONES RN, SILVA JB, SENTRY PARTICIPANTS GROUP: Skin and soft tissue infections in Latin American medical centers: four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. Diag. Microbiol. Infect. Dis. (2002) 44(3):281-288.
   PubMed Web of Science ®Google Scholar
• WAGENVOORT JH: Methicillin-resistant Staphylococcus aureus in ophthalmology, occurrence, sanitation measures and hygienic precautions. Dev. Ophthalmol. (2002) 33:199-206.
   PubMedGoogle Scholar
• WILSON WR, KARCHMER AW, DAJANI AS et al.: Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. JAMA (1995) 274(21):1706-1713.
   PubMed Web of Science ®Google Scholar
• KIRST HA, THOMPSON DG, NICAS TI: Historical yearly usage of vancomycin. Antimicob. Agents Chemother. (1998) 42(5):1303-1304.
   PubMed Web of Science ®Google Scholar
• WUNDERINK RG, RELLO J, CAMMARATA SK, CROOS-DABRERA RV, KOLLEF MH: Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 124(5):1789-1797.
   PubMed Web of Science ®Google Scholar
• WALSH TR, HOWE RA: The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus. Ann. Rev. Microbiol. (2002) 56:657-675.
   PubMed Web of Science ®Google Scholar
• GEISEL R, SCHMITZ FJ, FLUIT AC, LABISCHINSKI H: Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur. J. Clin. Micobiol. Infect. Dis. (2001) 20(10):685-697.
   PubMed Web of Science ®Google Scholar
• MACGOWAN AP: Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther. Drug Monit. (1998) 20(5):473-477.
   PubMed Web of Science ®Google Scholar
• COOPER MA, JIN YF, ASHBY JP, ANDREWS JM, WISE R: In vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin. J. Antimicob. Chemother. (1990) 26(2):203-207.
   PubMed Web of Science ®Google Scholar
• HANBERGER H, NILSSON LE, MALLER R, ISAKSSON B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs. Antimicob. Agents Chemother. (1991) 35(9):1710-1716.
   PubMed Web of Science ®Google Scholar
• LOWDIN E, ODENHOLT I, CARS O: In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis. Antimicob. Agents Chemother. (1998) 42(10):2739-2744.
   PubMed Web of Science ®Google Scholar
• MCDONALD PJ, CRAIG WA, KUNIN CM: Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J. Infect. Dis. (1977) 135(2):217-223.
   PubMed Web of Science ®Google Scholar
• ODENHOLT-TORNQVIST I, LOWDIN E, CARS O: Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicob. Agents Chemother. (1992) 36(9):1852-1858.
   PubMed Web of Science ®Google Scholar
• DUFFULL SB, BEGG EJ, CHAMBERS ST, BARCLAY ML: Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicob. Agents Chemother. (1994) 38(10):2480-2482.
   PubMed Web of Science ®Google Scholar
• SNYDMAN DR, JACOBUS NV, MCDERMOTT LA, LONKS JR, BOYCE JM: Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicob. Agents Chemother. (2000) 44(12):3447-3450.
   PubMed Web of Science ®Google Scholar
• AESCHLIMANN JR, ALLEN GP, HERSHBERGER E, RYBAK MJ: Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model. Antimicob. Agents Chemother. (2000) 44(11):2991-2998.
   PubMed Web of Science ®Google Scholar
• DIEKEMA DJ, PFALLER MA, SCHMITZ FJ et al.: Survey of infections due to staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. (2001) 32(Suppl 2):S114-S132.
   PubMed Web of Science ®Google Scholar
• EGUIA JM, LIU C, MOORE M et al.: Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clin. Infect. Dis. (2005) 40:1617-1624.
   PubMed Web of Science ®Google Scholar
• ARIAS CA, REYES J, ZUNIGA M et al.: Multicentere surveillance of antimicrobial resistance in enterococci and staphylococci from Colombian hospitals, 2001-2002. J. Antimicob. Chemother. (2003) 51:59-68.
   PubMed Web of Science ®Google Scholar
• SADER HS, JONES RN, ANDRADE-BAIOCCHI S, BIEDENBACH DJ, SENTRY PARTICIPANTS GROUP: Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diag. Microbiol. Infect. Dis. (2002) 44(3):273-280.
   PubMed Web of Science ®Google Scholar
• BALLOW CH, JONES RN, BIEDENBACH DJ, NORTH AMERICAN ZAPS RESEARCH GROUP: A multicenter evaluation of linezolid antimicrobial activity in North America. Diag. Microbiol. Infect. Dis. (2002) 43(1):75-83.
   PubMed Web of Science ®Google Scholar
• WIDMER AF, FREI R, RAJACIC Z, ZIMMERLI W: Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. (1990) 162(1):96-102.
   PubMed Web of Science ®Google Scholar
• PASCUAL A: Pathogenesis of catheter-related infections: lessons for new designs. Clin. Microbiol. Infect. (2002) 8(5):256-264.
   PubMed Web of Science ®Google Scholar
• WIEDERHOLD NP, COYLE EA, RAAD II, PRINCE RA, LEWIS RE: Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia. J. Antimicob. Chemother. (2005) 55(5):792-795.
   PubMed Web of Science ®Google Scholar
• STEWART PS, COSTERTON JW: Antibiotic resistance of bacteria in biofilms. Lancet (2001) 358(9276):135-138.
   PubMed Web of Science ®Google Scholar
• WIDMER AF: New developments in diagnosis and treatment of infection in orthopedic implants. Clin. Infect. Dis. (2001) 33(Suppl 2):S94-S106.
   PubMed Web of Science ®Google Scholar
• JOHNSON AP, UTTLEY AH, WOODFORD N, GEORGE RC: Resistance to vancomycin and teicoplanin: an emerging clinical problem. Clin. Microbiol. Rev. (1990) 3(3):280-291.
   PubMed Web of Science ®Google Scholar
• SRINIVASAN A, DICK JD, PERL TM: Vancomycin resistance in staphylococci. Clin. Microbiol. Rev. (2002) 15(3):430-438.
   PubMed Web of Science ®Google Scholar
• TENOVER FC, BIDDLE JW, LANCASTER MV: Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg. Infect. Dis. (2001) 7(2):327-332.
   PubMed Web of Science ®Google Scholar
• VOORN GP, KUYVENHOVEN J, GOESSENS WH et al.: Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicob. Agents Chemother. (1994) 38(3):487-493.
   PubMed Web of Science ®Google Scholar
• HIRAMATSU K, HANAKI H, INO T, YABUTA K, OGURI T, TENOVER FC: Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicob. Chemother. (1997) 40(1):135-136.
   PubMed Web of Science ®Google Scholar
• ATKINSON BA, LORIAN V: Antimicrobial agent susceptibility patterns of bacteria in hospitals from 1971 to 1982. J. Clin. Microbiol. (1984) 20(4):791-796.
   PubMed Web of Science ®Google Scholar
• SMITH TL, PEARSON ML, WILCOX KR et al.: Emergence of vancomycin resistance in Staphylococcus aureus. New Engl. J. Med. (1999) 340(7):493-501.
   PubMed Web of Science ®Google Scholar
• TSAKRIS A, PAPADIMITRIOU E, DOUBOYAS J, STYLIANOPOULOU F, MANOLIS E: Emergence of vancomycin-intermediate Staphylococcus aureus and S. sciuri, Greece. Emerg. Infect. Dis. (2002) 8(5):536-537.
   PubMed Web of Science ®Google Scholar
• KIM MN, HWANG SH, PYO YJ, MUN HM, PAI CH: Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea. J. Clin. Microbiol. (2002) 40(4):1376-1380.
   PubMed Web of Science ®Google Scholar
• KRALOVIC SM, DANKO LH, ROSELLE GA: Laboratory reporting of Staphylococcus aureus with reduced susceptibility to vancomycin in United States Department of Veterans Affairs facilities. Emerg. Infect. Dis. (2002) 8(4):402-407.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASECONTROL AND PREVENTION: Interim guidelines for prevention and control of staphylococcal infection associated with reduced susceptibility to vancomycin. MMWR Morb. Mortal. Wkly Rep. (1997) 46(27):626-628.
   PubMedGoogle Scholar
• CENTERS FOR DISEASECONTROL AND PREVENTION: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997. MMWR Morb. Mortal. Wkly Rep. (1997) 46(33):765-766.
   PubMedGoogle Scholar
• HAMILTON-MILLER JM: Vancomycin-resistant Staphylococcus aureus: a real and present danger? Infection (2002) 30(3):118-124.
   PubMed Web of Science ®Google Scholar
• GOETTSCH W, BRONZWAER SL, DE NEELING AJ et al.: Standardization and quality assurance for antimicrobial resistance surveillance of Streptococcus pneumoniae and Staphylococcus aureus within the European Antimicrobial Resistance Surveillance System (EARSS). Clin. Microbiol. Infect. (2000) 6(2):59-63.
   PubMed Web of Science ®Google Scholar
• SAKOULAS G, MOISE-BRODER PA, SCHENTAG JJ, FORREST A, MOELLERING RC, ELIOPOULOS GM: Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. (2004) 42(6):2398-402.
   PubMed Web of Science ®Google Scholar
• LACY MK, TESSIER PR, NICOLAU DP, NIGHTINGALE CH, QUINTILIANI R: Comparison of vancomycin pharmacodynamics (1 g every 12 or 24 h) against methicillin-resistant staphylococci. Int. J. Antimicrob. Agents (2000) 15(1):25-30.
   PubMed Web of Science ®Google Scholar
• WOOTTON M, WALSH TR, MACGOWAN AP: Evidence for reduction in breakpoints used to determine vancomycin suscpetibility in Staphylococcus aureus. Antimicob. Agents Chemother. (2005) 49(9):3982-3983.
   PubMed Web of Science ®Google Scholar
• FRIDKIN SK: Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin. Infect. Dis. (2001) 32(1):108-115.
   PubMed Web of Science ®Google Scholar
• HUSSAIN FM, BOYLE-VAVRA S, SHETE PB, DAUM RS: Evidence for a continuum of decreased vancomycin susceptibility in unselected Staphylococcus aureus clinical isolates. J. Infect. Dis. (2002) 186(5):661-667.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASECONTROL AND PREVENTION: Investigation and control of vancomycin-intermediate and -resistant Staphylococcus aureus: a guide for health departments and infection control personnel. Atlanta, GA. 2004.
   Google Scholar
• MARKOWITZ N, POHLOD DJ, SARAVOLATZ LD, QUINN EL: In vitro susceptibility patterns of methicillin-resistant and-susceptible Staphylococcus aureus strains in a population of parenteral drug abusers from 1972 to 1981. Antimicob. Agents Chemother. (1983) 23(3):450-457.
   PubMed Web of Science ®Google Scholar
• SABATH LD, WHEELER N, LAVERDIERE M, BLAZEVIC D, WILKINSON BJ: A new type of penicillin resistance of Staphylococcus aureus. Lancet (1977) 1(8009):443-447.
   PubMed Web of Science ®Google Scholar
• WATANAKUNAKORN C: Antibiotic-tolerant Staphylococcus aureus. J. Antimicob. Chemother. (1978) 4(6):561-568.
   PubMed Web of Science ®Google Scholar
• MAPLE PA, HAMILTON-MILLER JM, BRUMFITT W: World-wide antibiotic resistance in methicillin-resistant Staphylococcus aureus. Lancet (1989) 1(8637):537-540.
   PubMed Web of Science ®Google Scholar
• SORRELL TC, PACKHAM DR, SHANKER S, FOLDES M, MUNRO R: Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann. Intern. Med. (1982) 97(3):344-350.
   PubMed Web of Science ®Google Scholar
• VAN DER AUWERA P: Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. Antimicob. Agents Chemother. (1989) 33(10):1783-1790.
   PubMed Web of Science ®Google Scholar
• FRANCHI D, CLIMO MW, WONG AH, EDMOND MB, WENZEL RP: Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci. Clin. Infect. Dis. (1999) 29(6):1566-1568.
   PubMed Web of Science ®Google Scholar
• LAWRENCE T, ROTSTEIN C, BEAM TR, JR, GORZYNSKI EA, AMSTERDAM D: In vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci. Antimicob. Agents Chemother. (1993) 37(4):896-900.
   PubMed Web of Science ®Google Scholar
• SCHMITZ FJ, KREY A, GEISEL R, VERHOEF J, HEINZ HP, FLUIT AC: Susceptibility of 302 methicillin-resistant Staphylococcus aureus isolates from 20 European university hospitals to vancomycin and alternative antistaphylococcal compounds. Eur. J. Clin. Micobiol. Infect. Dis. (1999) 18(7):528-530.
   PubMed Web of Science ®Google Scholar
• CHA R, CHEUNG CA, RYBAK MJ: Assessment of daptomycin, linezolid, and vancomycin susceptibility and prevalence of vancomycin tolerance in staphylococci over years of vancomycin pressure. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. California, USA (27 – 30 September 2002) A-49.
   Google Scholar
• FRITSCHE TR, STEPHENS JS, JONES RN: Changing patterns of bacterial pathogens and their antimicrobial susceptibility profiles in patients hospitalized with pneumonia: report from the SENTRY Antimicrobial Surveillance Program. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (14 – 17 September 2003) C-2191.
   Google Scholar
• ROTUN SS, MCMATH V, SCHOONMAKER DJ, MAUPIN PS, TENOVER FC, HILL BC, ACKMAN DM: Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg. Infect. Dis. (1999) 5(1):147-149.
   PubMed Web of Science ®Google Scholar
• SIERADZKI K, LESKI T, TOMASZ A, DICK J, BORIO L: Evolution of a vancomycin-intermediate Staphylococcus aureus strain in vivo: multiple changes in the antibiotic resistance phenotypes of a single lineage of methicillin-resistant S. aureus under the impact of antibiotics administered for chemotherapy. J. Clin. Microbiol. (2003) 41(4):1687-1693.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASECONTROL AND PREVENTION: Staphylococcus aureus with reduced susceptibility to vancomycin--Illinois, 1999. MMWR Morb. Mortal. Wkly Rep. (2000) 48(51-52):1165-1167.
   PubMedGoogle Scholar
• HAGEMAN JC, PEGUES DA, JEPSON C et al.: Vancomycin-intermediate Staphylococcus aureus in a home health-care patient. Emerg. Infect. Dis. (2001) 7(6):1023-1025.
   PubMed Web of Science ®Google Scholar
• FRIDKIN SK, HAGEMAN J, MCDOUGAL LK et al.; VANCOMYCIN-INTERMEDIATE STAPHYLOCOCCUS AUREUS EPIDEMIOLOGY STUDY GROUP: Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001. Clin. Infect. Dis. (2003) 36(4):429-439.
   PubMed Web of Science ®Google Scholar
• PLOY MC, GRELAUD C, MARTIN C, DE LUMLEY L, DENIS F: First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital. Lancet (1998) 351(9110):1212.
   PubMed Web of Science ®Google Scholar
• HOWDEN BP, WARD PB, JOHNSON PD, CHARLES PG, GRAYSON ML: Low-level vancomycin resistance in Staphylococcus aureus--an Australian perspective. Eur. J. Clin. Micobiol. Infect. Dis. (2005) 24(2):100-108.
   PubMed Web of Science ®Google Scholar
• MURRAY RJ, SIEUNARINE K, WARD PB, PEARMAN JW: Emergence of heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) infection in Western Australia. Med. J. Aust. (2004) 181(4):227-228.
   PubMedGoogle Scholar
• WARD PB, JOHNSON PD, GRABSCH EA, MAYALL BC, GRAYSON ML: Treatment failure due to methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to vancomycin. Med. J. Aust. (2001) 175(9):480-483.
   PubMed Web of Science ®Google Scholar
• TRAKULSOMBOON S, DANCHAIVIJITR S, RONGRUNGRUANG Y et al.: First report of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Thailand. J. Clin. Microbiol. (2001) 39(2):591-595.
   PubMed Web of Science ®Google Scholar
• SNG LH, KOH TH, WANG GC, HSU LY, KAPI M, HIRAMATSU K: Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore. Int. J. Antimicrob. Agents (2005) 25(2):177-179.
   PubMed Web of Science ®Google Scholar
• CASSONE M, CAMPANILE F, PANTOSTI A, VENDITTI M, STEFANI S: Identification of a variant "Rome clone" of methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin, responsible for an outbreak in an intensive care unit. Microbial Drug Resistance-Mechanisms Epidemiology & Disease (2004)10(1):43-9.
   PubMed Web of Science ®Google Scholar
• MABED M, MAROUF S: Vancomycin-resistant Staphylococcus aureus in a bone marrow transplantation unit. Ann. Hematol. (2005) 84(2):133-135.
   PubMed Web of Science ®Google Scholar
• TENOVER FC, LANCASTER MV, HILL BC et al.: Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J. Clin. Microbiol. (1998) 36(4):1020-1027.
   PubMed Web of Science ®Google Scholar
• CUI L, MURAKAMI H, KUWAHARA-ARAI K, HANAKI H, HIRAMATSU K: Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50. Antimicob. Agents Chemother. (2000) 44(9):2276-2285.
   PubMed Web of Science ®Google Scholar
• HANAKI H, KUWAHARA-ARAI K, BOYLE-VAVRA S, DAUM RS, LABISCHINSKI H, HIRAMATSU K: Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicob. Chemother. (1998) 42(2):199-209.
   PubMed Web of Science ®Google Scholar
• WONG SS, NG TK, YAM WC, TSANG DN, WOO PC, FUNG SK, YUEN KY: Bacteremia due to Staphylococcus aureus with reduced susceptibility to vancomycin. Diag. Microbiol. Infect. Dis. (2000) 36(4):261-268.
   PubMed Web of Science ®Google Scholar
• REIPERT A, EHLERT K, KAST T, BIERBAUM G: Morphological and genetic differences in two isogenic Staphylococcus aureus strains with decreased susceptibilities to vancomycin. Antimicob. Agents Chemother. (2003) 47(2):568-576.
   PubMed Web of Science ®Google Scholar
• AYLIFFE GA: The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. (1997) 24(Suppl. 1):S74-S79.
   PubMedGoogle Scholar
• BRUCKNER R, BASSIAS J: In gram positive pathogens; carbohydrate catabolism pathways and regulation in staphylococci. ASM Press, Washington, D.C., (2000):339-344.
   Google Scholar
• CHARLES PG, WARD PB, JOHNSON PD, HOWDEN BP, GRAYSON ML: Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin. Infect. Dis. (2004) 38(3):448-451.
   PubMed Web of Science ®Google Scholar
• KURODA M, OHTA T, UCHIYAMA I et al.: Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet (2001) 357(9264):1225-1240.
   PubMed Web of Science ®Google Scholar
• LIU C, CHAMBERS HF: Staphylococcus aureus with heterogenous resistance to vancomycin: epidemiology, clinical significance and critical assessment of diagnostic methods. Antimicob. Agents Chemother. (2003) 47:3040-3045.
   PubMed Web of Science ®Google Scholar
• HIRAMATSU K, ARITAKA N, HANAKI H et al.: Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet (1997) 350(9092):1670-1673.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ, CHA R, CHEUNG CM, MEKA VG, KAATZ GW: Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. Diag. Microbiol. Infect. Dis. (2005) 51(2):119-125.
   PubMed Web of Science ®Google Scholar
• EQUIA JM, LIU C, MOORE M et al.: Low colonization prevalence of Staphylococcus aureus with reduced vancomycin susceptibility among patients undergoing hemodialysis in the San Francisco Bay area. Clin. Inf. Dis. (2005) 40(11):1617-1624.
   Google Scholar
• TALLENT SM, BISCHOFF T, CLIMO M, OSTROWSKY B, WENZEL RP, EDMOND MB: Vancomycin susceptibility of oxacillin-resistant Staphylococcus aureus isolates causing nosocomial bloodstream infections. J. Clin. Microbiol. (2002) 40(6):2249-2250.
   PubMed Web of Science ®Google Scholar
• SCHWABER MJ, WRIGHT SB, CARMELI Y, VENKATARAMAN L, DEGIROLAMI PC: Clinical implications of varying degrees of vancomycin susceptilibity in methicillin-resistant Staphylococcus aureus bacteremia. Emerg. Infect. Dis. (2003) 9(6):657-664.
   PubMed Web of Science ®Google Scholar
• HOWE RA, NOEL AR, BOWKER KE, WALSH TR, MACGOWAN AP: The prevalence of the heterogenously vancomycin intermediate Staphylococcus aureus (hVISA) in the USA. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (14-17 September 2003) C2-1828.
   Google Scholar
• PLIPAT N, LIVNI G, BERTRAM H, THOMSON RB, Jr: Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus. J. Clin. Microbiol. (2005) 43(5):2494-2496.
   PubMed Web of Science ®Google Scholar
• KHOSROVANEH A, RIEDERER K, SAEED S et al.: Frequency of reduced vancomycin susceptibility and heterogeneous subpopulation in persistent or recurrent methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2004) 38:1328-1330.
   PubMed Web of Science ®Google Scholar
• SIERADZKI K, ROBERTS RB, HABER SW, TOMASZ A: The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. New Engl. J. Med. (1999) 340(7):517-523.
   PubMed Web of Science ®Google Scholar
• ADHIKARI RP, SCALES GC, KOBAYASHI K, SMITH JM, BERGER-BACHI B, COOK GM: Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus. J. Antimicob. Chemother. (2004) 54(2):360-363.
   PubMed Web of Science ®Google Scholar
• HOWE RA, MONK A, WOOTTON M, WALSH TR, ENRIGHT MC: Vancomycin susceptibility within methicillin-resistant Staphylococcus aureus lineages. Emerging Infect. Dis. (2004) 10(5):855-857.
   PubMed Web of Science ®Google Scholar
• MOORE MR, PERDREAU-REMINGTON F, CHAMBERS HF: Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis. Antimicob. Agents Chemother. (2003) 47(4):1262-1266.
   PubMed Web of Science ®Google Scholar
• ARIZA J, PUJOL M, CABO J et al.: Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet (1999) 353(9164):1587-1588.
   PubMed Web of Science ®Google Scholar
• PERRY JD, JONES AL, GOULD FK: Glycopeptide tolerance in bacteria causing endocarditis. J. Antimicob. Chemother. (1999) 44(1):121-124.
   PubMed Web of Science ®Google Scholar
• NOBLE WC, VIRANI Z, CREE RG: Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol. Lett. (1992) 72(2):195-198.
   PubMed Web of Science ®Google Scholar
• ARTHUR M, DEPARDIEU F, REYNOLDS P, COURVALIN P: Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicob. Agents Chemother. (1999) 43(8):1875-1880.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASECONTROL AND PREVENTION: Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(26):565-567.
   PubMedGoogle Scholar
• CENTERS FOR DISEASECONTROL AND PREVENTION: Public health dispatch: vancomycin-resistant Staphylococcus aureus---Pennsylvania, 2002. MMWR Morb. Mortal. Wkly Rep. (2002) 51(40):902.
   PubMedGoogle Scholar
• KACICA M, MCDONALD LC: Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb. Mortal. Wkly Rep. (2004) 53(15):322-323.
   PubMedGoogle Scholar
• CHANG S, SIEVERT DM, HAGEMAN JC et al.: Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. New Engl. J. Med. (2003) 348(14):1342-1347.
   PubMed Web of Science ®Google Scholar
• BOZDOGAN B, EDNIE L, CREDITO K, KOSOWSKA K, APPELBAUM PC: Derivatives of a vancomycin-resistant Staphylococcus aureus strain isolated at Hershey Medical Center. Antimicob. Agents Chemother. (2004) 48(12):4762-4765.
   PubMed Web of Science ®Google Scholar
• CLARK NC, WEIGEL LM, PATEL JB, TENOVER FC: Comparison of Tn1546-like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicob. Agents Chemother. (2005) 49(1):470-472.
   PubMed Web of Science ®Google Scholar
• FARBER BF, MOELLERING RC, Jr: Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicob. Agents Chemother. (1983) 23(1):138-141.
   PubMed Web of Science ®Google Scholar
• TANGE RA, KIEVIET HL, VON MARLE J, BAGGER-SJOBACK D, RING W: An experimental study of vancomycin-induced cochlear damage. Arch. Otorhinolaryngol. (1989) 246(2):67-70.
   PubMedGoogle Scholar
• MEYERHOFF WL, MAALE GE, YELLIN W, ROLAND PS: Audiologic threshold monitoring of patients receiving ototoxic drugs: preliminary report. Ann. Otol. Rhinol. Laryngol. (1989) 98(12:Pt 1):1-4.
   Google Scholar
• VAN DER HULST RJ, BOESCHOTEN EW, NIELSEN FW, STRUIJK DG, DRESCHLER WD, TANGE RA: Ototoxicity monitoring with ultra-high frequency audiometry in peritoneal dialysis patients treated with vancomycin or gentamicin. ORL J. Otorhinolaryngol. Relat. Spec. (1991) 53(1):19-22.
   PubMedGoogle Scholar
• ELTING LS, RUBENSTEIN EB, KURTIN D et al.: Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice. Cancer (1998) 83(12):2597-607.
   PubMed Web of Science ®Google Scholar
• COHEN E, DADASHEV A, DRUCKER M, SAMRA Z, RUBINSTEIN E, GARTY M: Once-daily versus twice-daily intravenous administration of vancomycin for infections in hospitalized patients. J. Antimicob. Chemother. (2002) 49(1):155-160.
   PubMed Web of Science ®Google Scholar
• GENDEH BS, GIBB AG, AZIZ NS, KONG N, ZAHIR ZM: Vancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicity. Otolaryngol. Head Neck Surg. (1998) 118(4):551-558.
   PubMed Web of Science ®Google Scholar
• CANTU TG, YAMANAKA-YUEN NA, LIETMAN PS: Serum vancomycin concentrations: reappraisal of their clinical value. Clin. Infect. Dis. (1994) 18(4):533-543.
   PubMed Web of Science ®Google Scholar
• GOETZ MB, SAYERS J: Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J. Antimicob. Chemother. (1993) 32(2):325-334.
   PubMed Web of Science ®Google Scholar
• MONROE SG, POLK R: Vancomycin. In: Antimicrobial Therapy and Vaccines. Yu V, Merigan T, Barriere S, Raoult D (Eds), Lippincott, Williams & Wilkins, MD, USA (1999):1007-1018.
   Google Scholar
• RYBAK MJ, ALBRECHT LM, BOIKE SC, CHANDRASEKAR PH: Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J. Antimicob. Chemother. (1990) 25(4):679-687.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ, ABATE BJ, KANG SL, RUFFING MJ, LERNER SA, DRUSANO GL: Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicob. Agents Chemother. (1999) 43(7):1549-1555.
   PubMed Web of Science ®Google Scholar
• HIDAYAT LK, HSU DI, QUIST R, SHRINER KA, WONG-BERINGER A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections. Arch. Intern. Med. (2006) 166:2138-2144.
   PubMed Web of Science ®Google Scholar
• RENZ CL, THURN JD, FINN HA, LYNCH JP, MOSS J: Antihistamine prophylaxis permits rapid vancomycin infusion. Crit. Care Med. (1999) 27(9):1732-1737.
   PubMed Web of Science ®Google Scholar
• RYBAK MJ, BAILEY EM, WARBASSE LH: Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin. Antimicob. Agents Chemother. (1992) 36(6):1204-1207.
   PubMed Web of Science ®Google Scholar
• KORMAN TM, TURNIDGE JD, GRAYSON ML: Risk factors for adverse cutaneous reactions associated with intravenous vancomycin. J. Antimicob. Chemother. (1997) 39(3):371-381.
   PubMed Web of Science ®Google Scholar
• VON DRYGALSKI A, CURTIS BR, BOUGIE DW et al.: Vancomycin-induced immune throbocytopenia. N. Engl. J. Med. (2007) 256:904-910.
   Google Scholar
• WOOD MJ: Comparative safety of teicoplanin and vancomycin. J. Chemother. (2000) 12(Suppl. 5):21-25.
   PubMedGoogle Scholar
• KAPLAN SL, DEVILLE JG, YOGEV R et al.: Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Ped. Infect. Dis. J. (2003) 22(8):677-686.
   PubMed Web of Science ®Google Scholar
• TICE AD, HOAGLUND PA, NOLET BR, MOZAFFARI E, HENDRICKSON JR: Vancomycin practice patterns and adverse events: OPAT outcomes registry. Pharmacotherapy (2000) 20(10):1249.
   Google Scholar
• FAGON J, PATRICK H, HAAS DW et al.: Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am. J. Resp. Crit. Care Med. (2000) 161(3:Pt 1):753-762.
   PubMed Web of Science ®Google Scholar
• RUBINSTEIN E, CAMMARATA S, OLIPHANT T, WUNDERINK R, LINEZOLID NOSOCOMIAL PNEUMONIA STUDY GROUP: Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin. Infect. Dis. (2001) 32(3):402-412.
   PubMed Web of Science ®Google Scholar
• ANDRES I, LOPEZ R, POU L, PINOL F, PASCUAL C: Vancomycin monitoring: one or two serum levels? Ther. Drug Monit. (1997) 19(6):614-619.
   PubMed Web of Science ®Google Scholar
• WYSOCKI M, DELATOUR F, FAURISSON F et al.: Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicob. Agents Chemother. (2001) 45(9):2460-2467.
   PubMed Web of Science ®Google Scholar
• CRUCIANI M, GATTI G, LAZZARINI L et al.: Penetration of vancomycin into human lung tissue. J. Antimicob. Chemother. (1996) 38(5):865-869.
   PubMed Web of Science ®Google Scholar
• LAMER C, DE BECO V, SOLER P et al.: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicob. Agents Chemother. (1993) 37(2):281-286.
   PubMed Web of Science ®Google Scholar
• LUTSAR I, MCCRACKEN GH, Jr, FRIEDLAND IR: Antibiotic pharmacodynamics in cerebrospinal fluid. Clin. Infect. Dis. (1998) 27(5):1117-1127.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-LACASA J, CABELLOS C, MARTOS A et al.: Experimental study of the efficacy of vancomycin, rifampicin and dexamethasone in the therapy of pneumococcal meningitis. J. Antimicob. Chemother. (2002) 49(3):507-513.
   PubMed Web of Science ®Google Scholar
• DI FILIPPO A, DE GAUDIO AR, NOVELLI A et al.: Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection. Chemother.(1998) 44(1):63-68.
   PubMed Web of Science ®Google Scholar
• KLEPSER ME, PATEL KB, NICOLAU DP, QUINTILIANI R, NIGHTINGALE CH: Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy (1998) 18(5):1069-1074.
   PubMed Web of Science ®Google Scholar
• ALBANÈSE J, LÉONE M, BRUGUEROLLE B, AYEM ML, LACARELLE B, MARTIN C: Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob. Agents Chemother. (2000) 44(5):1356-1358.
   PubMed Web of Science ®Google Scholar
• BYL B, JACOBS F, WALLEMACQ P et al.: Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion. Antimicrob. Agents Chemother. (2003) 47(6):2015-2017.
   PubMed Web of Science ®Google Scholar
• JAMES JK, PALMER SM, LEVINE DP, RYBAK MJ: Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob. Agents Chemother. (1996) 40(3):696-700.
   PubMed Web of Science ®Google Scholar
• MOISE PA, FORREST A, PALADINO JA, SCHENTAG JJ: Rapid response of methicillin-resistant Staphylococcus aureus infections to quinupristin/dalfopristin plus vancomycin in patients failing vancomycin. Pharmacotherapy (2002) 22(3):413.
   Google Scholar
• FREEMAN CD, QUINTILIANI R, NIGHTINGALE CH: Vancomycin therapeutic drug monitoring: is it necessary? Ann. Pharmacotherapy (1993) 27(5):594-598.
   Google Scholar
• LEADER WG, CHANDLER MH, CASTIGLIA M: Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet.(1995) 28(4):327-342.
   PubMed Web of Science ®Google Scholar
• MOELLERING RC, Jr: Monitoring serum vancomycin levels: climbing the mountain because it is there? Clin. Infect. Dis. (1994) 18(4):544-546.
   PubMed Web of Science ®Google Scholar
• SAUNDERS NJ: Vancomycin administration and monitoring reappraisal. J. Antimicob. Chemother. (1995) 36(2):279-282.
   PubMed Web of Science ®Google Scholar
• LODISE TP, MCKINNON PS: Epidemiology and outcomes of bacteremic Staphylococcus aureus pneumonia. Proceedings of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, USA (14 – 17 September 2003. K-765
   Google Scholar
• KIM SH, PARK WB, LEE KD et al.: Outcome of Staphylococcus aureus bacteremia in patients with eradicable foci versus noneradicable foci. Clin. Infect. Dis. (2003) 37(6):794-799.
   PubMed Web of Science ®Google Scholar
• LODISE TP, MCKINNON PS.SWIDERSKI: Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2003) 36(11):1418-1423.
   PubMed Web of Science ®Google Scholar
• MOISE-BRODER PA, SAKOULAS G, ELIOPOULOS GM, SCHENTAG JJ, FORREST A, MOELLERING RC: Accessory gene regulatory group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin. Infect. Dis. (2004) 38:1700-1705.
   PubMed Web of Science ®Google Scholar
• SAKOULAS G, ELIOPOULOS GM, MOELLERING RC: Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isoaltes with reduced susceptibility to vancomycin. Antimicob. Agents Chemother. (2002) 46:1492-502.
   PubMed Web of Science ®Google Scholar
• SAKOULAS G, ELIOPOULOS GM, MOELLERING RC: Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J. Infect. Dis. (2003) 187:929-938.
   PubMed Web of Science ®Google Scholar
• HYATT JM, MCKINNON PS, ZIMMER GS, SCHENTAG JJ: The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin. Pharmacokinet.(1995) 28(2):143-160.
   PubMed Web of Science ®Google Scholar
• MOISE PA, FORREST A, BHAVNANI SM, BIRMINGHAM MC, SCHENTAG JJ: Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am. J. Health Sys. Pharm. (2000) 57:S4-S9.
   PubMed Web of Science ®Google Scholar
• MOISE-BRODER PA, FORREST A, BIRMINGHAM MC, SCHENTAG JJ: Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. (2004) 43(13):925-942.
   PubMed Web of Science ®Google Scholar
• JEFFRES MN, ISAKOW W, DOHERTY JA et al.: Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest (2006) 130(4):947-955.
   PubMed Web of Science ®Google Scholar
• SORRELL TC, COLLIGNON PJ: A prospective study of adverse reactions associated with vancomycin therapy. J. Antimicob. Chemother. (1985) 16(2):235-241.
   PubMed Web of Science ®Google Scholar
• TRABER PG, LEVINE DP: Vancomycin ototoxicity in patient with normal renal function. Ann. Intern. Med. (1981) 95(4):458-460.
   PubMed Web of Science ®Google Scholar
• BAILIE GR, NEAL D: Vancomycin ototoxicity and nephrotoxicity: a review. Med. Toxicol. Adv. Drug Exp. (1988) 3(5):376-386.
   PubMedGoogle Scholar
• PEA F, PORRECA L, BARALDO M, FURLANUT M: High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J. Antimicob. Chemother. (2000) 45(3):329-335.
   PubMed Web of Science ®Google Scholar
• POLARD E, LE BOUQUIN V, LE CORRE P et al.: Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients. Ther. Drug Monit. (1999) 21(4):395-403.
   PubMed Web of Science ®Google Scholar
• SCHENTAG JJ: Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance. J. Chemother. (1999) 11(6):426-439.
   PubMed Web of Science ®Google Scholar
• KARAM CM, MCKINNON PS, NEUHAUSER MM, RYBAK MJ: Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. Pharmacotherapy (1999) 19(3):257-266.
   PubMed Web of Science ®Google Scholar
• TUNKEL AR, HARTMAN BJ, KAPLAN SL et al.: Practice guidelines for the management of bacterial meningitis. Clin. Infect. Dis. (2004) 39:1267-1284.
   PubMed Web of Science ®Google Scholar
• NIEDERMAN MS, CRAVEN DE, BONTEN MJ, CHASTRE J, CRAIG WA, FAGON J: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Resp. Crit. Care Med. (2005) 171:388-416.
   PubMed Web of Science ®Google Scholar
• BADDOUR LM, WILSON WR, BAYER AS et al.: Infective endocarditis diagnosis, antimicrobial therapy, and management of complications. Circulation (2005) 111:3167-3184.
   Web of Science ®Google Scholar
• MELLA S, SEPULVEDA M, BELLO H, DOMINGUEZ M, GONZALEZ G, ZEMELMAN R: Cloxacilin and vancomycin bacterial action against oxalicin-susceptible Staphylococcus aureus. Revista Medica de Chile (2001) 129:(2):224-226,.
   PubMed Web of Science ®Google Scholar
• FOWLER VG, Jr, SANDERS LL, SEXTON DJ et al.. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin. Infect. Dis. (1998) 27(3):478-486.
   PubMed Web of Science ®Google Scholar
• GONZALEZ C, RUBIO M, ROMERO-VIVAS J, GONZALEZ M, PICAZO JJ: Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin. Infect. Dis. (1999) 29(5):1171-1177.
   PubMed Web of Science ®Google Scholar
• MARR KA, KONG L, FOWLER VG et al.: Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int. (1998) 54(5):1684-1689.
   PubMed Web of Science ®Google Scholar
• RAAD I, BOMPART F, HACHEM R: Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur. J. Clin. Micobiol. Infect. Dis. (1999) 18(3):199-202.
   PubMed Web of Science ®Google Scholar
• STEVENS DL, HERR D, LAMPIRIS H, HUNT JL, BATTS DH, HAFKIN B: Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. (2002) 34(11):1481-1490.
   PubMed Web of Science ®Google Scholar
• WUNDERINK RG, CAMMARATA SK, OLIPHANT TH, KOLLEF MH: Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin. Ther. (2003) 25:980-992.
   PubMed Web of Science ®Google Scholar
• KOLLEF MH, RELLO J, CAMMARATA SK, CROOS-DABRERA RV, WUNDERINK RG: Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. (2004) 30(3):388-394.
   PubMed Web of Science ®Google Scholar
• SHARPE JN, SHIVELY EH, POLK HC: Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am. J. Surg. (2005) 189:425-428.
   PubMed Web of Science ®Google Scholar
• WEIGELT J, ITANI K, STEVENS D, LAU W, DRYDEN M, KNIRSCH C: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicob. Agents Chemother. (2005) 49(6):2260-2266.
   PubMed Web of Science ®Google Scholar
• MOISE PA, SCHENTAG JJ: Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int. J. Antimicrob. Agents (2000) 16(Suppl 1):S31-S34.
   PubMedGoogle Scholar
• GOPAL V, BISNO AL, SILVERBLATT FJ: Failure of vancomycin treatment in Staphylococcus aureus endocarditis. In vivo and in vitro observations. JAMA (1976) 236(14):1604-1606.
   PubMed Web of Science ®Google Scholar
• JACKSON MA, HICKS RA: Vancomycin failure in staphylococcal endocarditis. Ped. Infect. Dis. J. (1987) 6(8):750-752.
   PubMed Web of Science ®Google Scholar
• LODISE TP, MCKINNON PS, SWIDERSKI L, RYBAK MJ: Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin. Infect. Dis. (2003) 36(11):1418-1423.
   PubMed Web of Science ®Google Scholar
• LEVINE DP, FROMM BS, REDDY BR: Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. (1991) 115(9):674-680.
   PubMed Web of Science ®Google Scholar
• SMALL PM, CHAMBERS HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicob. Agents Chemother. (1990) 34(6):1227-1231.
   PubMed Web of Science ®Google Scholar
• FRIDKIN SK, LAWTON R, EDWARDS JR, TENOVER FC, MCGOWAN JE, Jr, GAYNES RP: Intensive Care Antimicrobial Resistance Epidemiology Project, National Nosocomial Infections Surveillance Systems Hospitals. Monitoring antimicrobial use and resistance: comparison with a national benchmark on reducing vancomycin use and vancomycin-resistant enterococci. Emerg. Infect. Dis. (2002) 8(7):702-707.
   PubMed Web of Science ®Google Scholar
• Recommendations forpreventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC): Am. J. Infect. Control (1995) 23(2):87-94.
   PubMed Web of Science ®Google Scholar
• NAIMI TS, ANDERSOND, O’BOYLE C et al.: Vancomycin-intermediate Staphylococcus aureus with phenotypic susceptibility to methicillin in a patient with recurrent bacteremia. Clin. Inf. Dis. (2003) 36(12):1609-1612.
   Google Scholar